A device designed to help overweight type-2 diabetes patients manage their disease is due to be the subject of a new clinical trial.
The Tantalus System is an implantable device that has already been approved for sale in Europe and is now about to undergo trials in the US.
Scientists at the New York-Presbyterian Hospital/Weill Cornell Medical Centre are recruiting patients with type-2 diabetes and a body mass index (BMI) between 28 and 45.
Participants will be fitted with the new device, which senses electrical activity in the stomach and applies electrical stimulation when the patient eats.
A previous study has suggested that the device is effective at reducing hunger and body weight in patients in need of obesity treatment.
Dr Louis Aronne, principal investigator and clinical professor of medicine at Weill Cornell Medical College, commented: "Even with current medications and lifestyle changes, controlling type-2 diabetes in patients who are overweight can be difficult.
"This new treatment potentially offers new hope for patients who have been unsuccessful in managing their diabetes and weight."